Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Peritoneal-plasma barrier

P Jacquet1, P H Sugarbaker

  • 1Department of Gynecological Oncology, University of Texas, M.D. Anderson Cancer Center, Houston 77030, USA.

Cancer Treatment and Research
|January 1, 1996
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

[Organophosphorus poisoning: Towards enzymatic treatments].

Annales pharmaceutiques francaises·2019
Same author

The current practice of cytoreductive surgery and HIPEC for colorectal peritoneal metastases: Results of a worldwide web-based survey of the Peritoneal Surface Oncology Group International (PSOGI).

European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology·2018
Same author

Increased safety of surgical glove application: the under/over method.

Annals of the Royal College of Surgeons of England·2017
Same author

[Decontamination of organophosphorus compounds: Towards new alternatives].

Annales pharmaceutiques francaises·2017
Same author

Long-term regional chemotherapy for patients with epithelial malignant peritoneal mesothelioma results in improved survival.

European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology·2017
Same author

Management of an inguinal hernia in patients with pseudomyxoma peritonei.

European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology·2017

The peritoneal-plasma barrier limits drug absorption into the bloodstream, enhancing cancer treatment effectiveness in the abdominal cavity. Understanding this barrier is crucial for optimizing locoregional chemotherapy and reducing systemic toxicity.

Area of Science:

  • Pharmacology
  • Oncology
  • Physiology

Background:

  • The peritoneal-plasma barrier is a critical factor in abdominal cancer treatment.
  • This barrier restricts drug absorption from the peritoneal cavity into the bloodstream.
  • Understanding its properties is key to improving locoregional chemotherapy efficacy.

Purpose of the Study:

  • To elucidate the physical nature of the peritoneal-plasma barrier.
  • To understand its role in drug sequestration and transport.
  • To inform treatment planning for abdominal malignancies.

Main Methods:

  • Pharmacologic studies investigating drug transport across the peritoneal membrane.
  • Analysis of solute transfer resistance.
  • Review of existing literature on peritoneal drug disposition.

Related Experiment Videos

Main Results:

  • The peritoneal-plasma barrier significantly limits drug resorption, enhancing locoregional drug concentration.
  • The capillary wall is identified as the primary resistance to large solute transfer.
  • Mesothelium and interstitium play a lesser role; their removal does not impact postoperative chemotherapy.

Conclusions:

  • The peritoneal-plasma barrier's function is vital for locoregional chemotherapy in abdominal cancers.
  • Further pharmacologic research is needed to fully define this barrier.
  • Targeting or understanding this barrier can optimize cancer therapy and minimize side effects.